Dual diagnosis refers to the co-occurrence of a psychiatric disorder and a substance use disorder in the same person. It is not a rare presentation — it is one of the most common clinical configurations seen in psychiatric practice.
The relationship between psychiatric conditions and substance use is complex and bidirectional. Substances may be used to manage psychiatric symptoms — anxiety, depression, psychosis, trauma — and prolonged use can itself produce or exacerbate psychiatric conditions. Disentangling cause and effect is one of the central diagnostic challenges in dual diagnosis work, and it has direct implications for treatment.
Common presentations include depression with alcohol use disorder, anxiety disorders with stimulant or benzodiazepine dependence, bipolar disorder with substance use, PTSD with alcohol or substances as a coping mechanism, psychotic disorders with cannabis or stimulant use, and personality disorders with polydrug use.
The psychiatric condition may be primary — pre-existing the substance use — or secondary — emerging as a consequence of it. In many cases, both are true to some degree.
A person with a dual diagnosis who receives treatment for only one of the two conditions is statistically likely to relapse in both. Treating the psychiatric condition without addressing the substance use leaves a major maintaining factor in place. Treating the substance use without addressing the underlying psychiatric condition leaves the patient without the psychological resources needed to sustain recovery.
Effective dual diagnosis treatment is integrated — it addresses both conditions simultaneously, within a unified clinical framework, by a team that understands both domains.
At IsraClinic, dual diagnosis cases are managed within the clinic's standard clinical framework. The multidisciplinary team — psychiatrist, neurologist, psychotherapist, and clinical curator — works collegially on the case as a whole.
Assessment begins with a comprehensive psychiatric and substance use history — covering the timeline of both conditions, the pattern of substance use, its relationship to mood and mental state, previous treatment attempts, and the patient's current functioning.
Physical assessment including laboratory testing is standard — to evaluate the effects of substance use on physical health, identify organic contributions, and ensure safe clinical management.
Psychological assessment provides information about the personality structure and psychological factors contributing to both dimensions.
Differential diagnosis is essential: many symptoms of active substance use or withdrawal can mimic or mask psychiatric conditions. The assessment is structured to establish the clearest possible clinical picture before a treatment plan is developed.
Treatment is individualised and integrated. The clinical team develops a single, unified plan addressing the psychiatric condition and the substance use as interconnected dimensions of the patient's situation.
Pharmacotherapy addresses the psychiatric condition with medication selected based on the full clinical picture — including substance use history and interaction considerations. Digital prescriptions are issued through the Yarpa system.
Psychotherapy is a central component. Cognitive Behavior Therapy (CBT) addresses both psychiatric symptoms and the patterns that maintain substance use. Where trauma is a significant factor — as it frequently is — EMDR or trauma-focused CBT may be incorporated.
All treatment follows the Psychoergonomic Method — comprehensive assessment of the full person, treatment that accounts for all contributing factors, and ongoing adjustment as the clinical picture evolves.
If psychiatric symptoms and substance use are occurring together — whether or not it is clear which came first — an integrated specialist assessment is appropriate. Dual diagnosis responds to the right treatment approach.
IsraClinic accepts patients for in-person consultation in Tel Aviv and online, in English, Russian and Hebrew. No referral is required.
Clinical Reviewer: Dr. Mark Zevin, MD — Senior Psychiatrist, IsraClinic | Last reviewed: 2026
When psychiatric symptoms and substance use occur together, integrated specialist treatment makes a significant difference. Our team is available in English, Russian and Hebrew.